New research to be presented at this year's European Congress on Obesity (ECO 2025, Malaga, Spain, 11-14 May) shows that women are much more aware of knowledgeable about the obesity drugs GLP-1/GIP ...

The first GLP-1 weight-loss pill is a step closer to hitting the market. Eli Lilly said its experimental pill met its goals ...

Researchers at Mass General Brigham found that by December 2023, over one-third of all new prescriptions for type 2 diabetes ...

Novo Nordisk, the maker of Ozempic and Wegovy, has also jumped into the legal fight —this time by intervening in the OFA’s lawsuit against the FDA. The company supports the agency’s move to restrict ...

The tortoise (Eli Lilly) has caught the hare (Novo Nordisk), according to a report from BMO Capital Markets, which cites the superior commercial and clinical portfolios of the Indianapolis company ...

The analyst highlights that Lilly’s drugs, Mounjaro and Zepbound, will likely keep gaining U.S. market share from Novo ...

Scholar Rock Holding Corporation's apitegromab shows promise for SMA treatment, aims for 2025 launch. Click for my updated ...

COLUMBUS — Ohio Attorney General Dave Yost has sent letters to 14 medical spas throughout the state warning them to stop making false or misleading claims about their versions of popular weight-loss ...

Ohio Attorney General Dave Yost has sent letters to 14 medical spas throughout the state warning them to stop making false or ...

Researchers found that by December 2023, more than 1 in 3 of the medications being started for type 2 diabetes treatment were GLP-1RA-based medications.

Ohio Attorney General Dave Yost issued a warning to several Ohio medical spas over their alleged claims regarding weight-loss drugs.

Several Ohio medical spas including two in the Mahoning Valley were sent letters by the Ohio Attorney General's Office ...